Journals / Turkish Journal of Pharmaceutical Sciences / 2021 / Cilt: 18 - Sayı: 4

Development of an Aloe vera-based Emulgel for the Topical Delivery of Desoximetasone

Dezoksimetazonun Topikal Uygulaması İçin Aloe vera Bazlı Bir Emüljelin Geliştirilmesi

Pages
90–100
Publication Date
2022-11-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Physicochemical characteristics and enhanced in vitro permeation of DMS from Aloe vera emulgel highlight its suitability to be efficiently employed for the topical treatment of skin ailments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Desoximetasone (DMS) is a widely recommended drug for the topical treatment of plaque psoriasis.
📊
Key Findings & Data:Materials and Methods: Different formulations (DE1-DE4) of Aloe vera emulgel were prepared using dispersion technique, wherein varying concentrations of propylene glycol (6-14% w/w) and carbopol 934 (0.5-1.0% w/w) were used.
💡
Conclusion & Impact:Conclusion: Physicochemical characteristics and enhanced in vitro permeation of DMS from Aloe vera emulgel highlight its suitability to be efficiently employed for the topical treatment of skin ailments.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Desoximetasone (DMS) is a widely recommended drug for the topical treatment of plaque psoriasis. However, low water solubility and short half life of DMS present major obstacles in the development of an effective topical formulation. Thus, there is a demand for the development of a safe and effective topical system to deliver hydrophobic DMS. The present study aimed to develop an Aloe vera-based emulgel formulation to ensure enhanced skin deposition of DMS for effective treatment of plaque psoriasis. Materials and Methods: Different formulations (DE1-DE4) of Aloe vera emulgel were prepared using dispersion technique, wherein varying concentrations of propylene glycol (6-14% w/w) and carbopol 934 (0.5-1.0% w/w) were used. Results: Zetasizer measurements revealed that the globule size of the formulations ranged from 10.34 µm±0.9 to 14.60 µm±1.4 (n=50). Extrudability analysis for the DE3 and DE2 formulations revealed an extrudability of 5.6±0.11 g/cm2and 5.8±0.13 g/cm2 , respectively. The pH of the formulations was recorded in the range of 5.8-6.8. Among these formulations, DE3 showed a maximum drug content of 94.64%±0.29 (n=3), and thus was used for further in vitro evalutions. A texture analyzer showed that an optimized DE3 formulation was firmer and exhibited optimal spreadability in comparison with the DE2 formulation. For DE3, the mean max force that represented “firmness” was recorded to be 833.37 g, where as the mean area, denoting “work of shear”, was 324.230 g.sec. The DE3 formulation exhibited DMS permeation of 95.40±1.6% over a period of 7 h, as detrmined using an in house fabricated Franze diffusion cell. Evaluation of in vitro release kinetics revealed that the release of DMS fitted into the Korsmeyer-Peppas model. Conclusion: Physicochemical characteristics and enhanced in vitro permeation of DMS from Aloe vera emulgel highlight its suitability to be efficiently employed for the topical treatment of skin ailments.

Özet

Amaç: Desoximetazon (DMS), plak psöriasisin topikal tedavisi için yaygın olarak önerilen bir ilaçtır. Ancak, DMS’nin düşük suda çözünürlüğü ve kısa yarı ömrü, etkili bir topikal formülasyonun geliştirilmesinde büyük engeller oluşturmaktadır. Bu nedenle, hidrofobik DMS vermek için güvenli ve etkili bir topikal sistemin geliştirilmesine yönelik bir talep vardır. Bu çalışma, plak psöriasisin etkili tedavisi için DMS’nin deride daha fazla birikmesini sağlamak için Aloe vera bazlı bir emüljel formülasyonu geliştirmeyi amaçlamıştır. Gereç ve Yöntemler: Aloe vera emüljelinin farklı formülasyonları (DE1-DE4), değişen konsantrasyonlarda propilen glikol (%6-14 w/w) ve karbopol 934 (%0,5-%1,0 w/w) içeren dispersiyon tekniği kullanılarak hazırlanmıştır. Bulgular: Zetasizer ölçümleri, formülasyonların globül boyutunun 10,34 µm±0,9 ila 14,60 µm±1,4 (n=50) arasında değiştiğini ortaya koymuştur. DE3 ve DE2 formülasyonları için ekstrüde edilebilirlik analizi, sırasıyla 5,6±0,11 g/cm2ve 5,8±0,13 g/cm2 ’lik bir ekstrüde edilebilirlik ortaya koymuştur. Bu formülasyonlar arasında DE3, %94,64±0,29 (n=3) maksimum ilaç içeriği göstermiş ve bu nedenle daha ileri in vitro değerlendirmeler için kullanılmuştır. Bir doku analiz cihazı, optimize edilmiş bir DE3 formülasyonunun DE2 formülasyonu ile karşılaştırıldığında daha sıkı olduğunu ve optimal yayılabilirlik sergilediğini göstermiştir. DE3 için, “sertliği” temsil eden ortalama maksimum kuvvet 833,37 g olarak kaydedilirken, “kesme işini” ifade eden ortalama alan 324,230 g sn bulunmuştur. DE3 formülasyonu tarafımızdan üretilmiş bir Franze difüzyon hücresi kullanılarak belirlendiği üzere, 7 saatlik bir süre boyunca %95,40±1,6 DMS geçirgenliği sergilemiştir. İn vitro salım kinetiğinin değerlendirilmesi, DMS salımının Korsmeyer-Peppas modeline uyduğunu ortaya çıkarmıştır.

🔖

Cite This Article

SAINY, J., ATNERIYA, U., KORI, J. L., MAHESHWARI, R. (2022). Development of an Aloe vera-based Emulgel for the Topical Delivery of Desoximetasone. Turkish Journal of Pharmaceutical Sciences, Cilt: 18 - Sayı: 4, 90–100. https://ajindex.com/articles/613609

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Stark HJ, Boehnke K, Mirancea N, Willhauck MJ, Pavesio A, Fusenig NE, Boukamp P. Epidermal homeostasis in long-term scaffold-enforced skin equivalents. J Investig Dermatol Symp Proc. 2006;11:93-105.
  2. Grubauer G, Feingold KR, Elias PM. Relationship of epidermal lipogenesis to cutaneous barrier function. J Lipid Res. 1987;28:746-752.
  3. Kuchekar BA, Pujari RR, Kuchekar SB, Dhole SN, Mule PM. Psoriasis a comprehensive. Int J Pharm Life Sci. 2011;2:857-877.
  4. Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother. 2010;11:1999-2009.
  5. Imran KT, Gore S, Giradkar P. A review advances in topical drug delivery system. Int J Pharm Res Allied Sci. 2011:1:14-23.
  6. Kumar V, Mahant S, Rao R, Nanda S. Emulgel based topical delivery system for loratadine. ADMET DMPK. 2015;2:254-271.
  7. Khunt DM, Mishra AD, Shah DR. Formulation design & development of piroxicam emulgel. Int J PharmTech Res. 2012;4:1332-1344.
  8. Susmitha A, Gudas GK. Formulation and evalaution of chlorzoxazone transdermal emulgel by using natural penetration enhancer. Int J Phar Anal Res. 2019;8:38-44.
  9. Berdey II, Voyt OI. Rheological properties of emulgel formulations based on different gelling agent. The Pharma Innovation. 2016;5:76-79.
  10. Kumari A, Singh A, Saurabh SS, Rathore KS, Issarani R. Formulation and evaluation of lycopene emulgel. Indo Am J Pharm Sci. 2015;2:1013-1027.
  11. Khullar, R, Kumar D, Seth N, Saini S. Formulation and evaluation of mefenamic acid emulgel for topical delivery. Saudi Pharm J. 2012;20:63-67.
  12. Vyas SP, Khar RK. Controlled drug delivery: Concepts and advances Vallabh Prakashan; pp. 2002;418-422.
  13. Singla V, Saini S, Joshi B, Rana AC. Emulgel: a new platform for topical drug delivery. Int J Pharm Bio Sci. 2012;3:485-498.
  14. Thanushree HR, Kumar GBK, Acharya A. Formulation development of diclofenac sodium emulgel using aloe vera gel for transdermal drug delivery system. Int J Pharm Sci Technol. 2017;10:3858-3865. Prajapati MN. Emulgels: A novel approach to topical drug delivery. Int J Univ Pharm Biosci 2013;2134-2148.
  15. Kasliwal N, Derele D, Negi J, Gohil K. Effect of permeation enhancer an the release and pharmacokinetics of meloxicam gel formulation through rat skin. Asian J Pharm Sci. 2008;3:193-199.
  16. Panwar AS, Upadhyay N, Bairagi M, Gujar S, Darwhekar GN, Jain DK. Emulgel: A review. Asian J Pharm Life Sci. 2011;1:333-343.
  17. Raju YP, Haritha K, Satyanarayana RP, Vandana KR, Bindu DT, Vinesha V, Chowdary VH. Formulation and characterization of aceclofenac -aloe vera transemulgel. Curr Dr